PL445003A1 - Kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie - Google Patents

Kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie

Info

Publication number
PL445003A1
PL445003A1 PL445003A PL44500323A PL445003A1 PL 445003 A1 PL445003 A1 PL 445003A1 PL 445003 A PL445003 A PL 445003A PL 44500323 A PL44500323 A PL 44500323A PL 445003 A1 PL445003 A1 PL 445003A1
Authority
PL
Poland
Prior art keywords
application
pharmaceutical composition
cancer treatment
cancer
treatment
Prior art date
Application number
PL445003A
Other languages
English (en)
Inventor
Marek RUSIN
Barbara ŁASUT-SZYSZKA
Original Assignee
Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy filed Critical Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
Priority to PL445003A priority Critical patent/PL445003A1/pl
Priority to PCT/PL2024/050036 priority patent/WO2024248641A1/en
Publication of PL445003A1 publication Critical patent/PL445003A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie w leczeniu lub zapobieganiu chorobie nowotworowej.
PL445003A 2023-05-26 2023-05-26 Kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie PL445003A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL445003A PL445003A1 (pl) 2023-05-26 2023-05-26 Kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie
PCT/PL2024/050036 WO2024248641A1 (en) 2023-05-26 2024-05-27 Pharmaceutical composition, particularly for use in the treatment or prevention of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445003A PL445003A1 (pl) 2023-05-26 2023-05-26 Kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie

Publications (1)

Publication Number Publication Date
PL445003A1 true PL445003A1 (pl) 2024-12-02

Family

ID=93658281

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445003A PL445003A1 (pl) 2023-05-26 2023-05-26 Kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie

Country Status (2)

Country Link
PL (1) PL445003A1 (pl)
WO (1) WO2024248641A1 (pl)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GLAZYRIN A.L. I IN.: "Int J Oncol. 2002 Jan;20(1):201-5.", "MOLECULAR MECHANISM(S) OF ACTINOMYCIN-D INDUCED SENSITIZATION OF PANCREATIC CANCER CELLS TO CD95 MEDIATED APOPTOSIS." *
KRZEŚNIAK M. I IN.: "Cell Signal. 2020 May;69:109552. doi: 10.1016/j.cellsig.2020.109552.", "SYNERGISTIC ACTIVATION OF P53 BY ACTINOMYCIN D AND NUTLIN-3A IS ASSOCIATED WITH THE UPREGULATION OF CRUCIAL REGULATORS AND EFFECTORS OF INNATE IMMUNITY." *
ŁASUT-SZYSZKA B. I IN.: "Int J Mol Sci. 2021 Oct 14;22(20):11072. doi: 10.3390/ijms222011072.", "TRANSCRIPTOME ANALYSIS OF CELLS EXPOSED TO ACTINOMYCIN D AND NUTLIN-3A REVEALS NEW CANDIDATE P53-TARGET GENES AND INDICATES THAT CHIR-98014 IS AN IMPORTANT INHIBITOR OF P53 ACTIVITY." *
RADFAR S. I IN.: "Gastroenterol Clin Biol. 2000 Dec;24(12):1191-6.", "TUMOR ESCAPE MECHANISM INVOLVING FAS AND FAS-L MOLECULES IN HUMAN COLORECTAL TUMORS." *

Also Published As

Publication number Publication date
WO2024248641A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
EA202190630A1 (ru) Способы комбинированной терапии
CA3246093A1 (en) PARP1 INHIBITORS AND THEIR USES
MY208549A (en) Parp1 inhibitors
NZ787393A (en) New methylquinazolinone derivatives
CA3117687C (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12022550438A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
CR20240144A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
PH12022550286A1 (en) Deuterated compounds for use in the treatment of cancer
MX2025008920A (es) Inhibidores de parp1 triciclicos y usos de estos
CL2025001913A1 (es) Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso.
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
CO2022000270A2 (es) Inhibidores de enzimas
MX2022016496A (es) Combinacion de un inhibidor del bromodominio cbp/p300 y un inhibidor del egfr para su uso en el tratamiento de la cpnm con mutacion del egfr.
MX2022003396A (es) Uso de inhibidores de dkk-1 para tratar el cancer.
PL445003A1 (pl) Kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie
MX2025011417A (es) Programa de dosificacion de un inhibidor de her.2
MX2022011138A (es) Efecto contra coronavirus y aplicacion de inhibidor de fosfatidilinositol 4-cinasa.
MX2024012565A (es) Composiciones farmaceuticas de mosunetuzumab y metodos de uso
MX2024014771A (es) Terapia combinada
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
MX2025001279A (es) Aril-triazolilo y antagonistas gpr84 relacionados y usos de estos
PE20250073A1 (es) Formulacion de sotorasib
PL420267A1 (pl) Ekstrakt z grzyba poliporoidalnego, kompozycja zawierająca ten ekstrakt oraz jego zastosowanie